bcl‐2 protein expression is associated with better prognosis in colorectal cancer

Authors:

Abstract
Aims: To investigate the expression of bcl‐2 in colorectal carcinoma and to examine its association with mediators of apoptosis (p53 and mdm‐2), clinicopathological features and long‐term outcome.Methods and results: We determined by immunohistochemistry the expression of bcl‐2 in 102 colorectal carcinomas with 10‐year follow‐up. In 66 of these cases in which we had previously assessed p53 status, no correlation was seen between bcl‐2 and p53. The mdm‐2 protein was not detected in any of the 66 cases. Cytoplasmic staining of the bcl‐2 gene product was seen in the tumour cells of 22 cases (22%). Using a polymerase chain reaction technique we showed that overexpression of bcl‐2 was not due to rearrangement of the bcl‐2 gene. Expression of bcl‐2 protein was related to tumour grade but was unrelated to patient age, sex, tumour site, tumour size or Dukes' stage. There was a trend towards increased survival in those whose tumours expressed bcl‐2 protein (P = 0.055). When entered into a multivariate analysis, this survival difference was independent of tumour stage (P = 0.05).Conclusions: These results suggest that bcl‐2 expression in colorectal carcinoma is associated with a better long‐term prognosis.